Menu
Search
|

Menu

Close
X

Esperion Therapeutics Inc ESPR.OQ (NASDAQ Stock Exchange Global Market)

36.78 USD
-0.62 (-1.66%)
As of Sep 17
Previous Close 37.40
Open 37.34
Volume 111,032
3m Avg Volume 177,772
Today’s High 37.34
Today’s Low 36.05
52 Week High 60.98
52 Week Low 33.13
Shares Outstanding (mil) 25.69
Market Capitalization (mil) 1,444.21
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.77 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY19
146
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
1.061
FY18
-7.542
FY17
-7.019
FY16
-3.325
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
8.24
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
1.24
14.55
LT Debt to Equity (MRQ)
vs sector
0.09
10.20
Return on Investment (TTM)
vs sector
-61.42
14.48
Return on Equity (TTM)
vs sector
-61.71
15.78

EXECUTIVE LEADERSHIP

Timothy Mayleben
President, Chief Executive Officer, Director, Since 2012
Salary: $600,000.00
Bonus: $115,000.00
Richard Bartram
Chief Financial Officer, Since 2018
Salary: $330,000.00
Bonus: --
Narendra Lalwani
Executive Vice President - Research & Development, Since 2018
Salary: $430,000.00
Bonus: --
Mark Glickman
Chief Commercial Officer, Since 2018
Salary: $322,500.00
Bonus: --
Nicole Vitullo
Lead Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3891 Ranchero Dr Ste 150
ANN ARBOR   MI   48108-2837

Phone: +1734.8873903

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

SPONSORED STORIES